Research, symptoms, care, and policy developments related to long COVID and other post-viral illness.
A June 2026 trial found metformin missed its main test for preventing post-COVID symptoms, though a secondary clinician-diagnosed long-COVID signal was lower. CDC and IDSA still center vaccination and timely antiviral treatment for higher-risk patients.
A May 27, 2026 study suggests long COVID can be missed when health systems rely on diagnosis codes alone. Here is why estimates differ, what CDC says about diagnosis, and when to get checked.
A new randomized study suggests fluvoxamine may ease long COVID fatigue for some people, but the finding is narrow, early, and not enough to change routine care. CDC guidance still says long COVID is diagnosed clinically, there is no approved test, and treatment is focused on symptom management while research continues.
New CDC guidance and fresh research reinforce the same core message: long COVID can follow even a mild infection, normal tests do not rule it out, and the best proven way to lower risk is still reducing the chances of severe COVID-19. Early studies on fatigue treatments and supplements are interesting, but they are not yet practice-changing. New U.S. data also suggest long COVID still falls unevenly across communities, which matters for access to diagnosis and care.
CDC’s updated Long COVID guidance keeps the focus on symptoms, function, and follow-up care. The key takeaway for readers is simple: a normal lab workup does not automatically rule out Long COVID.
A COVID booster may still lower the chance of long COVID, but it is not a guarantee. The latest CDC guidance says vaccination remains the best available tool to prevent long COVID, while newer studies suggest protection that is real but not complete.
End of content
End of content
